Skip to content
2000
Volume 21, Issue 4
  • ISSN: 1573-398X
  • E-ISSN: 1875-6387

Abstract

Pneumonia, a widespread respiratory infection affecting the alveoli and lung parenchyma, continues to be a major global health concern, particularly in children. Despite advancements in vaccine development and anti-infective therapies, pneumonia is a leading cause of death, particularly among children and the elderly. It accounts for approximately 14% of all deaths in children under five years of age globally, with over 700,000 deaths occurring annually. In adults, especially those over 65 years of age, pneumonia significantly increases mortality, contributing to over 1 million deaths yearly worldwide. Community-acquired Pneumonia (CAP) is predominantly caused by , , and . is the leading pathogen, particularly in infants, the elderly, and immunocompromised individuals, often resulting in severe clinical presentations. causes milder, atypical pneumonia, commonly referred to as “walking pneumonia”, affecting young adults and adolescents. is also a significant cause of mild to moderate respiratory infections, particularly in school-aged children. The identification of these pathogens is critical for guiding empirical antimicrobial therapy, as the clinical severity and response to treatment vary with each microorganism. This review aimed to explore the intricacies of pneumonia pathogenesis and provide insights into the role of various microorganisms in its development. By emphasizing the importance of timely and appropriate antimicrobial therapy, the review further aims to underscore the need for rapid, accurate diagnostic tests capable of detecting pathogens and antibiotic resistance. Therefore, improving diagnostic capabilities and targeted treatments is essential for effective pneumonia management. The complexity of pneumonia pathogenesis and the variety of causative microorganisms require rapid, accurate diagnostic tests to guide appropriate therapy.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X339936250107062518
2025-01-20
2025-11-16

  • From This Site

    /content/journals/crmr/10.2174/011573398X339936250107062518
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MammasI.N. SpandidosD.A. Paediatric virology in the hippocratic corpus.Exp. Ther. Med.201612254154910.3892/etm.2016.342
     [Google Scholar]
  2. LofflerW. Disorders of the chest. Lancet.194726473444
     [Google Scholar]
  3. RokitanskyC. Inflammations of the lungs (pneumonia). In: Manual of Pathological Anatomy. Vol 2. London: Sydenham Society; 1852.
  4. LimW.S. Pneumonia—overview.Encyclopedia of respiratory medicineAcademic Press202218519710.1016/B978‑0‑12‑801238‑3.11636‑8
     [Google Scholar]
  5. MandellL.A. NiedermanM.S. Aspiration pneumonia.N. Engl. J. Med.2019380765166310.1056/NEJMra171456230763196
     [Google Scholar]
  6. WuB.G. SegalL.N. The lung microbiome and its role in pneumonia.Clin. Chest Med.201839467768910.1016/j.ccm.2018.07.00330390741
     [Google Scholar]
  7. JoséR.J. PeriselnerisJ.N. BrownJ.S. Community-acquired pneumonia.Curr. Opin. Pulm. Med.201521321221810.1097/MCP.000000000000015025775050
     [Google Scholar]
  8. KieningerA.N. LipsettP.A. Hospital-acquired pneumonia: Pathophysiology, diagnosis, and treatment.Surg. Clin. North Am.2009892439461, ix10.1016/j.suc.2008.11.00119281893
     [Google Scholar]
  9. ModiA.R. KovacsC.S. Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention.Cleve. Clin. J. Med.2020871063363910.3949/ccjm.87a.1911733004324
     [Google Scholar]
  10. KohbodiG.A. RajasuryaV. NoorA. Ventilator-associated pneumonia.StatPearlsStatPearls Publishing2023
     [Google Scholar]
  11. SattarS.B. SharmaS. HeadleyA. Bacterial pneumonia.StatPearlsStatPearls Publishing2023
     [Google Scholar]
  12. CillónizC. EwigS. PolverinoE. MarcosM.A. EsquinasC. GabarrúsA. MensaJ. TorresA. Microbial aetiology of community-acquired pneumonia and its relation to severity.Thorax201166434034610.1136/thx.2010.14398221257985
     [Google Scholar]
  13. TorresA. NiedermanM.S. ChastreJ. EwigS. Fernandez-VandellosP. HanbergerH. KollefM. Li BassiG. LunaC.M. Martin-LoechesI. PaivaJ.A. ReadR.C. RigauD. TimsitJ.F. WelteT. WunderinkR. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia.Eur. Respir. J.2017503170058210.1183/13993003.00582‑201728890434
     [Google Scholar]
  14. PrinaE. RanzaniO.T. TorresA. Community-acquired pneumonia.Lancet201538699981097110810.1016/S0140‑6736(15)60733‑426277247
     [Google Scholar]
  15. CillonizC, Martin-Loeches I, Garcia-Vidal C, San JA, Torres A. Microbial etiology of pneumonia: Epidemiology, diagnosis and resistance patterns.Int J Mol Sci.201617122120
     [Google Scholar]
  16. TroegerC BlackerB KhalilIA Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.The Lancet Infect. Dis.201818111191121010.1016/S1473‑3099(18)30310‑4
     [Google Scholar]
  17. KomiyaK. RubinB.K. KadotaJ. MukaeH. AkabaT. MoroH. AokiN. TsukadaH. NoguchiS. ShimeN. TakahashiO. KohnoS. Prognostic implications of aspiration pneumonia in patients with community acquired pneumonia: A systematic review with meta-analysis.Sci. Rep.2016613809710.1038/srep3809727924871
     [Google Scholar]
  18. TorresA. PeetermansW.E. ViegiG. BlasiF. Risk factors for community-acquired pneumonia in adults in Europe: A literature review.Thorax201368111057106510.1136/thoraxjnl‑2013‑20428224130229
     [Google Scholar]
  19. FarooquiH. JitM. HeymannD.L. ZodpeyS. Burden of severe pneumonia, pneumococcal pneumonia and pneumonia deaths in Indian states: Modelling based estimates.PLoS One2015106e012919110.1371/journal.pone.012919126086700
     [Google Scholar]
  20. EshwaraV. MukhopadhyayC. RelloJ. Community-acquired bacterial pneumonia in adults: An update.Indian J. Med. Res.2020151428730210.4103/ijmr.IJMR_1678_1932461392
     [Google Scholar]
  21. GrousdJ.A. RichH.E. AlcornJ.F. Host-pathogen interactions in gram-positive bacterial pneumonia.Clin. Microbiol. Rev.2019323e00107-1810.1128/CMR.00107‑1831142498
     [Google Scholar]
  22. ParkerD. AhnD. CohenT. PrinceA. Innate immune signaling activated by MDR bacteria in the airway.Physiol. Rev.2016961195310.1152/physrev.00009.201526582515
     [Google Scholar]
  23. KutterJ.S. SpronkenM.I. FraaijP.L. FouchierR.A.M. HerfstS. Transmission routes of respiratory viruses among humans.Curr. Opin. Virol.20182814215110.1016/j.coviro.2018.01.00129452994
     [Google Scholar]
  24. Phillips-HoulbracqM. RicardJ.D. FoucrierA. Yoder-HimesD. GaudryS. BexJ. MessikaJ. MargetisD. ChatelJ. DobrindtU. DenamurE. RouxD. Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence.Int. J. Med. Microbiol.2018308229029610.1016/j.ijmm.2018.01.00329325882
     [Google Scholar]
  25. WalterJ.M. WunderinkR.G. Severe respiratory viral infections.Infect. Dis. Clin. North Am.201731345547410.1016/j.idc.2017.05.00428687214
     [Google Scholar]
  26. SubramanianK Iovino F, Tsikourkitoudi F, Merkl P, Ahmed S, Berry SB, Aschtgen MS, Svensson M, Bergman P, Sotiriou GA, Normark BH. Mannose receptor-derived peptides neutralize pore- forming toxins and reduce inflammation and development of pneumococcal disease.EMBO Molecular Medicine2010121110.15252/emmm.202012695
     [Google Scholar]
  27. GuinD. YadavS. SinghP. SinghP. ThakranS. KukalS. KanojiaN. PaulP.R. PattnaikB. SardanaV. GroverS. HasijaY. SasoL. AgrawalA. KukretiR. Human genetic factors associated with pneumonia risk, a cue for COVID-19 susceptibility Infection, genetics and evolution.J. Mol. Epidemiol. Evol. Genet. Infect. Dis.2022102105299
     [Google Scholar]
  28. SantoroF. IannelliF. PozziG. Genomics and genetics of streptococcus pneumoniae.Microbiol. Spectr.20197310.1128/microbiolspec.GPP3‑0011‑2018
     [Google Scholar]
  29. AlibertiS. Dela Cruz, C.S., Amati, F., Sotgiu, G., Restrepo, M.I. Community-acquired pneumonia. The Lancet20213981030390691910.1016/S0140‑6736(21)00630‑9
     [Google Scholar]
  30. MattilaJ.T. FineM.J. LimperA.H. MurrayP.R. ChenB.B. LinP.L. Pneumonia. Treatment and diagnosis.Ann. Am. Thorac. Soc.2014114S189S192
     [Google Scholar]
  31. BhuiyanM.U. BlythC.C. WestR. LangJ. RahmanT. GranlandC. de GierC. BorlandM.L. ThorntonR.B. KirkhamL.A.S. MartinA. RichmondP.C. SmithD.W. JaffeA. SnellingT.L. Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children.BMC Pulm. Med.20191917110.1186/s12890‑019‑0835‑530940126
     [Google Scholar]
  32. MalechH.L. DeLeo, F.R., Quinn, M.T. The role of neutrophils in the immune system: an overview. In: Neutrophil. Methods Mol Biol. Vol 2087. Clifton, NJ: Springer; 2020. p. 3–10.10.1007/978‑1‑0716‑0154‑9_1
  33. GuoK. ChengJ. LiK. WangL. LvY. CaoD. Diagnosis and detection of pneumonia using weak-label based on X-ray images: A multi-center study.BMC Med. Imaging202323120910.1186/s12880‑023‑01174‑438087255
     [Google Scholar]
  34. TorresA. CillónizC. Clinical management of bacterial pneumonia.Cham (CH): Springer International Publishing; 2015.10.1007/978‑3‑319‑22062‑8
     [Google Scholar]
  35. TorresA. CillonizC. NiedermanM.S. MenéndezR. ChalmersJ.D. WunderinkR.G. van der PollT. Pneumonia.Nat. Rev. Dis. Primers2021712510.1038/s41572‑021‑00259‑033833230
     [Google Scholar]
  36. KalilA.C. MeterskyM.L. KlompasM. MuscedereJ. SweeneyD.A. PalmerL.B. NapolitanoL.M. O’GradyN.P. BartlettJ.G. CarratalàJ. El SolhA.A. EwigS. FeyP.D. FileT.M.Jr RestrepoM.I. RobertsJ.A. WatererG.W. CruseP. KnightS.L. BrozekJ.L. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society.Clin. Infect. Dis.2016635e61e11110.1093/cid/ciw35327418577
     [Google Scholar]
  37. MetlayJ.P. WatererG.W. LongA.C. AnzuetoA. BrozekJ. CrothersK. CooleyL.A. DeanN.C. FineM.J. FlandersS.A. GriffinM.R. MeterskyM.L. MusherD.M. RestrepoM.I. WhitneyC.G. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the american thoracic society and infectious diseases society of America.Am. J. Respir. Crit. Care Med.20192007e45e6710.1164/rccm.201908‑1581ST31573350
     [Google Scholar]
  38. ClaessensY.E. DebrayM.P. TubachF. BrunA.L. RammaertB. HausfaterP. NaccacheJ.M. RayP. ChoquetC. CaretteM.F. MayaudC. LeportC. DuvalX. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia.Am. J. Respir. Crit. Care Med.2015192897498210.1164/rccm.201501‑0017OC26168322
     [Google Scholar]
  39. DingX. XuJ. ZhouJ. LongQ. Chest CT findings of COVID-19 pneumonia by duration of symptoms.Eur. J. Radiol.202012710900910.1016/j.ejrad.2020.10900932325282
     [Google Scholar]
  40. LongL. ZhaoH.T. ZhangZ.Y. WangG.Y. ZhaoH.L. Lung ultrasound for the diagnosis of pneumonia in adults.Medicine2017963e571310.1097/MD.000000000000571328099332
     [Google Scholar]
  41. Ogawa KitsiosG.D. Iwata, M., Terasawa, T. Sputum gram stain for bacterial pathogen diagnosis in community-acquired pneumonia: A systematic review and bayesian meta-analysis of diagnostic accuracy and yield. Clinical infectious diseases: An official publication of the infectious diseases society of America.Clin. Infect. Dis.202071349951310.1093/cid/ciz876
     [Google Scholar]
  42. FukuyamaH. YamashiroS. KinjoK. TamakiH. KishabaT. Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia: A prospective observational study.BMC Infect. Dis.201414153410.1186/1471‑2334‑14‑53425326650
     [Google Scholar]
  43. KhaleelM. Samreen, S., Sirangi, S., Dinesh EM., Padmaja, RM., Dhanekula, K. Evaluation of a rapid urine antigen detection assay as a point-of-care test in the diagnosis of community-acquired pneumonia.Cureus2023158e4407810.7759/cureus.44078
     [Google Scholar]
  44. HellouMM. GórskaA. MazzaferriF. CremoniniE. GentilottiE. De NardoP. PoranI. LeeflangM.M. TacconelliE. PaulM. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: A systematic review and meta-analysis.Clin. Microbiol. Infect.2021273341351
     [Google Scholar]
  45. YuV.L. StoutJ.E. Rapid diagnostic testing for community-acquired pneumonia: Can innovative technology for clinical microbiology be exploited?Chest200913661618162110.1378/chest.09‑093919995763
     [Google Scholar]
  46. BurnsB.L., Rhoads, D.D., Misra, A. The use of machine learning for image analysis artificial intelligence in clinical microbiology.J Clin Microbiol2023619e023362110.1128/jcm.02336‑21
     [Google Scholar]
  47. SerigstadS. Knoop, S.T., Markussen, D.L., Ulvestad, E., Bjørneklett, R.O., Ebbesen, M.H., Kommedal, Ø., Grewal, H.M.S. Diagnostic utility of oropharyngeal swabs as an alternative to lower respiratory tract samples for PCR-based syndromic testing in patients with community-acquired pneumonia.J Clin Microbiol2023169e005052310.1128/jcm.00505‑23
     [Google Scholar]
  48. SheR.C. ThurberA. HymasW.C. StevensonJ. LangerJ. LitwinC.M. PettiC.A. Limited utility of culture for Mycoplasma pneumoniae and Chlamydophila pneumoniae for diagnosis of respiratory tract infections.J. Clin. Microbiol.20104893380338210.1128/JCM.00321‑1020610673
     [Google Scholar]
  49. DungT.T.N. PhatV.V. VinhC. LanN.P.H. PhuongN.L.N. NganL.T.Q. ThwaitesG. ThwaitesL. RabaaM. NguyenA.T.K. DuyP.T. Development and validation of multiplex real-time PCR for simultaneous detection of six bacterial pathogens causing lower respiratory tract infections and antimicrobial resistance genes.BMC Infect. Dis.202424116410.1186/s12879‑024‑09028‑238326753
     [Google Scholar]
  50. FoxJ.D. Nucleic acid amplification tests for detection of respiratory viruses.J. Clin. Virol.200740(Suppl. 1)S15S23
     [Google Scholar]
  51. ShariatzadehM. R. MarrieT. J. Does sputum culture affect the management and/or outcome of community-acquired pneumonia?E. Mediterr. Health J.2009154792799
     [Google Scholar]
  52. BartlettJ.G. Decline in microbial studies for patients with pulmonary infections.Clin. Infect. Dis.200439217017210.1086/42149815307024
     [Google Scholar]
  53. FangZ. LiuQ. TangW. YuH. ZouM. ZhangH. XueH. LinS. PeiY. AiJ. ChenJ. Experience in the diagnosis and treatment of pneumonia caused by infection with Tropheryma whipplei: A case series.Heliyon202396e1713210.1016/j.heliyon.2023.e1713237484369
     [Google Scholar]
  54. TorresA. ArtigasA. FerrerR. Biomarkers in the ICU: Less is more?Intensive Care Med.20214719710010.1007/s00134‑020‑06271‑433057749
     [Google Scholar]
  55. LiuP. OhlC. JohnsonJ. WilliamsonJ. BeardsleyJ. LutherV. Frequency of empiric antibiotic de-escalation in an acute care hospital with an established antimicrobial stewardship program.BMC Infect. Dis.201616175110.1186/s12879‑016‑2080‑327955625
     [Google Scholar]
  56. WunderinkR.G. WatererG. Advances in the causes and management of community acquired pneumonia in adults.BMJ2017358j247110.1136/bmj.j247128694251
     [Google Scholar]
  57. KrishnamurthyA. PalomboEA. Current therapeutics and prophylactic approaches to treat pneumonia.In: Chattopadhyay D, editor. The Microbiology of Respiratory System Infections. 1st ed. London: Academic Press; 2016. p. 263–79.10.1016/B978‑0‑12‑804543‑5.00017‑8
     [Google Scholar]
  58. FileT.M.Jr LowD.E. EckburgP.B. TalbotG.H. FriedlandH.D. LeeJ. LlorensL. CritchleyI.A. ThyeD.A. PullmanJ. GiordanoP. WelkerJ. ManosP. MehraP. FileT. De SantoJ. VenkateswaraluB. Gerald SchrockC. TillisW. WinetzJ.A. GonzalezJ.M. RamageA. EisenhowerD.D. KoegelenbergC. EngelbrechtI. JurgensJ. MithaI. BreedtJ. GaniM. RoosJ. BassonM. Van ZylL. MeedingR. FulatM. Le RouxM. BonvehiP.E. GanahaM.C. GuriniA.L. Daniel LopardoG. CristinaL. Edwardo PrietoS. RodiguezC.G. Augusto TeijeiroR. Carmen PalloneE. PrylukaD.H. da CunhaC.A. da SilvaN.B. de Faria FreireA.T. Ferreira StarlingC.E. Costa FitermanJ. Gongora RubioF. Carlos LossoL. PatelliM. Souza LimaJ. Zimermann TeixeiraP.J. Carmo MoreiraM.A. Abreu de OliveiraJ.C. RoudasV. GamalE.A. LeschenkoI. RudnovV.A. YevdokimovaA.G. VertkinA.L. AmbalovY.M. DvoryashinaI.V. ZilberE. KhamitovR.F. GalustyanA.N. ReshetkoO.V. SeniorV.A. GrosanM.F. JimboreanG. LupseM. AronG. OlteanuD. PuschitaM. GavrisC. TudoracheV.M. YouroukovaV. PetkovaM. TroshanovaE. DzhabalyanM. KavtaradzeG. MakhviladzeM. TabukashviliR. PonsM. GarbinoJ. GenneD. RothenM. de SarachoJ.O. CapelasteguiA. MenendezR. TorresA. ShumC. FalcoV. BouzaE. BruJ-P. MissetB. MegarbaneB. SolletJ.P. MolinaJ-M. DalhoffK. LorenzJ. PetermannW. RohdeG. SchumannC. TasciS. ZerbstJ. Auch-SchwelkW. SuttorpN. HenrichR. FertlA. GroheC. JakobeitC. DeppermannK-M. Batura-GabryelH. Pupek-MusialikD. PiotrowiczP. MarciszC. CzarnobilskiK. JankowskaR. JanikK. Gutowska-JablonskaM. HamankiewiczM. KusJ. RydzewskiA. DulawaJ. ZiolkoE. BaranskaE. WendlandM. Trebas-PietrasE. TyszkiewicI. BonelliJ. BalikoZ. BisitsM. LosonczyG. MarkZ. AlbertI. FrancovszkyE. FonayK. Tetiana PertsevaT. YefimovV. HavrysyukV. MelnykV. YashynaL. MonogarovaN. KolchynY. DutkaR. SmolyanyiO. TryshchukN. KaydashevI. RodionovaV. NeykoV. ChopeyI. AleknieneB. KramiliusG. NaudziunasS. MiliauskasS. NausedieneV. ValaviciusA. Mitic-MilikicM. CeleketicD. LazicZ. MilinicN. PejcicT. SuklesK. JaanusM. MeristeS. Ahmad MahayiddinD.H.A. Bin Abdul MuttalifA.P. Kuang KiatK. BinteR. ManapA. bt Md TarekhN.A. AnekthananonT. MootsikapunP. IntalapapornP. PothiratC. HorsinP. ChurchottawornC. WattanathumA. DukatA. PlutinskyJ. FOCUS 1 investigators FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.J. Antimicrob. Chemother.201166(Suppl. 3)iii19iii3210.1093/jac/dkr09621482566
     [Google Scholar]
  59. KazmierczakK.M. BiedenbachD.J. HackelM. RabineS. de JongeB.L.M. BouchillonS.K. SahmD.F. BradfordP.A. Global dissemination of bla KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam.Antimicrob. Agents Chemother.20166084490450010.1128/AAC.00107‑1627161636
     [Google Scholar]
  60. BassettiM. EcholsR. MatsunagaY. AriyasuM. DoiY. FerrerR. LodiseT.P. NaasT. NikiY. PatersonD.L. PortsmouthS. Torre-CisnerosJ. ToyoizumiK. WunderinkR.G. NagataT.D. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.Lancet Infect. Dis.202121222624010.1016/S1473‑3099(20)30796‑933058795
     [Google Scholar]
  61. JonesR.N. SaderH.S. MendesR.E. FlammR.K. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the united states: Report of ceftaroline activity from the sentry antimicrobial surveillance program (1998–2011).Diagn. Microbiol. Infect. Dis.201375110710910.1016/j.diagmicrobio.2012.08.02423009730
     [Google Scholar]
  62. WuJ.Y. SrinivasP. PogueJ.M. Cefiderocol: A novel agent for the management of multidrug-resistant gram-negative organisms.Infect. Dis. Ther.202091174010.1007/s40121‑020‑00286‑632072491
     [Google Scholar]
  63. FileT.M.Jr GoldbergL. DasA. SweeneyC. SaviskiJ. GeloneS.P. SeltzerE. PauknerS. WichaW.W. TalbotG.H. GasinkL.B. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: The phase III lefamulin evaluation against pneumonia (LEAP 1) trial.Clin. Infect. Dis.201969111856186710.1093/cid/ciz09030722059
     [Google Scholar]
  64. AlexanderE. GoldbergL. DasA.F. MoranG.J. SandrockC. GasinkL.B. SperaP. SweeneyC. PauknerS. WichaW.W. GeloneS.P. SchranzJ. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia.JAMA2019322171661167110.1001/jama.2019.1546831560372
     [Google Scholar]
  65. HeY.S. YangM. LiuG. JiJ. QianS.Y. Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia.Pediatr. Pulmonol.20235872017202410.1002/ppul.2642637098833
     [Google Scholar]
  66. MonteiroJ.F. HahnS.R. GonçalvesJ. FrescoP. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.Pharmacol. Res. Perspect.201864e0042010.1002/prp2.42030156005
     [Google Scholar]
  67. HsuH.C. HuangP.W. ChoY.T. ChuC.Y. Cotrimoxazole as a preventative intervention for pneumocystis pneumonia in pemphigus patients treated with rituximab: A retrospective study.Dermatol. Ther.20231371561157610.1007/s13555‑023‑00953‑937322166
     [Google Scholar]
  68. IreguiM. WardS. ShermanG. FraserV.J. KollefM.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.Chest2002122126226810.1378/chest.122.1.26212114368
     [Google Scholar]
  69. ShindoY. ItoR. KobayashiD. AndoM. IchikawaM. GotoY. FukuiY. IwakiM. OkumuraJ. YamaguchiI. YagiT. TanikawaY. SuginoY. ShindohJ. OgasawaraT. NomuraF. SakaH. YamamotoM. TaniguchiH. SuzukiR. SaitoH. KawamuraT. HasegawaY. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: An observational cohort study.Lancet Infect. Dis.20151591055106510.1016/S1473‑3099(15)00151‑626145194
     [Google Scholar]
  70. BrambillaA.M. AlibertiS. PrinaE. NicoliF. FornoM.D. NavaS. FerrariG. CorradiF. PelosiP. BignaminiA. TarsiaP. CosentiniR. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia.Intensive Care Med.201440794294910.1007/s00134‑014‑3325‑524817030
     [Google Scholar]
  71. ManteroM. TarsiaP. GramegnaA. HenchiS. VanoniN. Di PasqualeM. Antibiotic therapy, supportive treatment and management of immunomodulation-inflammation response in community acquired pneumonia: review of recommendations.Multidiscip. Respir. Med.20171212610.1186/s40248‑017‑0106‑329034094
     [Google Scholar]
  72. SaimanL. MarshallB.C. Mayer-HamblettN. BurnsJ.L. QuittnerA.L. CibeneD.A. CoquilletteS. FiebergA.Y. AccursoF.J. CampbellP.W.III for the Macrolide Study Group Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial.JAMA2003290131749175610.1001/jama.290.13.174914519709
     [Google Scholar]
  73. AgarwalA.K. RajaA. BrownB.D. Chronic obstructive pulmonary disease.StatPearls.StatPearls Publishing2023
     [Google Scholar]
  74. WaltersJ.A.E. TangJ.N.Q. PooleP. Wood-BakerR. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.Cochrane Libr.201720193CD00139010.1002/14651858.CD001390.pub428116747
     [Google Scholar]
  75. LunaC.M. Impact of vaccination on the epidemiology and prognosis of pneumonia.Rev. Esp. Quimioter.2022351104110
     [Google Scholar]
  76. NabiB. RehmanS. AggarwalS. BabootaS. AliJ. Nano-based anti-tubercular drug delivery: An emerging paradigm for improved therapeutic intervention.Drug Deliv. Transl. Res.20201041111112110.1007/s13346‑020‑00786‑532418158
     [Google Scholar]
  77. WorthingtonR.J. MelanderC. Combination approaches to combat multidrug-resistant bacteria.Trends Biotechnol.201331317718410.1016/j.tibtech.2012.12.00623333434
     [Google Scholar]
  78. MarshD. BartucciR. SportelliL. Lipid membranes with grafted polymers: Physicochemical aspects.Biochim. Biophys. Acta Biomembr.200316151-2335910.1016/S0005‑2736(03)00197‑412948586
     [Google Scholar]
  79. SmolaM. VandammeT. SokolowskiA. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.Int. J. Nanomed20083111918488412
     [Google Scholar]
/content/journals/crmr/10.2174/011573398X339936250107062518
Loading
Exploring Pneumonia: Understanding its Epidemiology, Deciphering Pathogenic Complexities, and Developing Advanced Diagnostic and Therapeutic Approaches
Curr. Respir. Med. Rev. 21, 343 (2025); https://doi.org/10.2174/011573398X339936250107062518
/content/journals/crmr/10.2174/011573398X339936250107062518
/content/journals/crmr/10.2174/011573398X339936250107062518
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Community-acquired pneumonia; diagnostic tests; hospital-acquired pneumonia; microbial etiology; pathogenesis; pathogens; ventilation-associated pneumonia

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test